Thrombosis: The Leading Cause of Death in PNH1-5
During chronic hemolysis, excess free hemoglobin depletes plasma nitric oxide, leading to platelet activation and impaired fibrinolysis, thereby increasing the risk of thrombosis in both venous and arterial sites3
-
Thromboses (venous or arterial) account for approximately 40% to 67% of PNH-related deaths4
- First thrombotic event (TE) can be fatal4,6
- First TE increases risk for death 5- to 10-fold4
- Pulmonary embolism (PE) or deep vein thrombosis (DVT) is the most common clinical presentation1,4
- 15% of all thrombotic events were identified in the arterial circulation4
Pulmonary embolism (PE) is one of the most common clinical presentations.1,4
PNH patients are at risk for thrombotic events.7
- While risk of thrombosis increases with clone size, even patients with smaller clone sizes experience thrombosis7
- 60% of patients with PNH have evidence of undiagnosed thrombosis8
Clinical thrombosis has been identified in PNH patients with minimal hemolysis, no transfusion history, and less severe anemia. 4,9
*The majority of patients (63%) received concomitant anticoagulant therapy
10,11 The effect of anticoagulant withdrawal during Soliris treatment has not been studied.
10